



Apatinib as an alternative therapy for advanced hepatoc



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

423,000 Results

Any time ▾

Apatinib, a **selective vascular endothelial growth factor receptor 2-tyrosine kinase inhibitor**, has demonstrated activity against a wide range of solid tumors, including advanced hepatocellular carcinoma (HCC).

[Apatinib prevents natural killer cell dysfunction to ...](#)

 www.nature.com/articles/s41417-020-0186-7

Was this helpful?



[Apatinib treatment of advanced hepatocellular carcinoma ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408098>

Recently, **apatinib** also shows significant efficacy and well safety in patients with intermediate/**advanced hepatocellular carcinoma**. In the study, a total of 31 patients with **HCC** were administered **oral apatinib** 500mg once daily and the median TTP was 4.8 months. In this case study, the patient was administered **oral apatinib** 500mg daily.

Author: XueGang Yang, Ge Wu, GuoHui Xu Publish Year: 2019

[\(PDF\) Apatinib is effective for treatment of advanced ...](#)

<https://www.researchgate.net/publication/320937328...>

As **treatment** options for **hepatocellular carcinoma** (HCC) are currently limited, we evaluated the efficacy and safety of oral **apatinib**, a VEGFR-2 inhibitor, on patients with **advanced** HCC.

[A Study of Apatinib for Advanced Hepatocellular Carcinoma ...](#)

<https://clinicaltrials.gov/ct2/show/NCT02772029>

Apatinib plays **anti angiogenic** effect in the **treatment** of **malignant tumor** mainly through inhibition of VEGFR-2, in vivo and in vitro experiments showed good tumor growth inhibitory activity on glioma, this study aims to further verify the efficacy and safety of **Apatinib** for **first-line treatment failure hepatocellular carcinoma** patients, the primary endpoint is time to progression(TTP).

[Efficacy and Safety of apatinib in patients with ...](#)

global.bing.com

19-Jan-2020 11:30AM54978 words • 33 matches • 26 sources

iThenticate®

54978-Review-check.docx

Quotes Excluded
Bibliography Excluded16%

24

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 54978

Manuscript Type: MINIREVIEWS

Apatinib

as an alternative therapy for advanced hepatocellular carcinoma

Zhang XH *et al.* Apatinib for advanced HCC

Xi-Hao Zhang, Man-Qing Cao, Xiu-Xiu Li, Ti Zhang

Abstract

Angiogenesis plays an important role in the occurrence and development of tumor. Registered tyrosine kinase inhibitors targetting vascular endothelial growth factor reduce angiogenesis. Apatinib, a tyrosine kinase inhibitor, can specifically inhibit vascular endothelial growth factor receptor 2, showing encouraging anti-tumor effects in a variety of tumors including advanced hepatocellular carcinoma (HCC). This article intends to review the clinical research and application prospects of apatinib in the field of HCC.

Match Overview

1

Internet 169 words
crawled on 28-May-2020
www.oncotarget.com

3%

2

Internet 30 words
crawled on 18-Sep-2019
journals.sagepub.com

1%

3

Internet 27 words
crawled on 03-Jan-2020
practitioner.org

1%

4

Internet 25 words
crawled on 03-Dec-2019
www.ncbi.nlm.nih.gov

1%

5

Crossref 23 words
Jianming Xu, Yan Zhang, Ru Jia, Chunyan Yue *et al.* "Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Adva

1%

6

Internet 18 words
crawled on 04-Oct-2019
www.revisionnature.com

1%

7

Internet 18 words
crawled on 03-May-2020
www.ejgnet.com

1%

8

Internet 17 words
crawled on 23-Jan-2020
translational-medicine.biomedcentral.com

1%

9

Internet 16 words
crawled on 11-May-2020
hbsn.amagroups.com

1%

Internet 16 words

10%

FILE: 1 OF 11

Text-Only Report

国内版 国际版



Apatinib as an alternative therapy for advanced hepatocellular car



ALL

IMAGES

VIDEOS

500,000 Results

Any time ▾

Comparison of efficacy between TACE combined with apatinib ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536939>

May 26, 2017 · Primary **hepatocellular carcinoma (HCC)** is one of the most common malignant tumors in the world, and is the second cause of **cancer-related** deaths. 1 According to the Barcelona Clinic **Liver Cancer (BCLC)** clinical staging system, the **standard treatment** of HCCs in BCLC stages B and C are transcatheter arterial chemoembolization (TACE) and oral sorafenib. 2 Sorafenib is the first molecular targeted drug approved for the **treatment** ...

Cited by: 25

Author: Wei Lu, Xin-Li Jin, Chao Yang, Peng Du,...

Publish Year: 2017

Apatinib treatment may improve survival outcomes of ...

<https://journals.sagepub.com/doi/10.1177/1758835920937422?icid=int.sj-full-text.citing...>

Aims:This study aimed to (a) assess the effectiveness and safety of **apatinib** as a subsequent **treatment** for patients with sorafenib-resistant **hepatocellular carcinoma** ...

Efficacy of apatinib in advanced hepatocellular carcinoma ...

<https://pubmed.ncbi.nlm.nih.gov/31786861>

Apatinib showed promising **therapeutic effects** on **advanced HCC** with **lung metastasis**, highlighting a population that could benefit preferentially from this **treatment**. Efficacy of **apatinib** in **advanced hepatocellular carcinoma** with **lung metastasis**: a retrospective, multicenter study

Targeted therapy for hepatocellular carcinoma | Signal ...

<https://www.nature.com/articles/s41392-020-00264-x>

Aug 11, 2020 · Bettinger, D. et al. Stereotactic body radiation **therapy as an alternative treatment** for patients with **hepatocellular carcinoma** compared to sorafenib: a propensity score analysis. **Liver Cancer** 8 ...